Literature DB >> 33281999

Comparison of 18F-NaF PET/CT with Other Imaging Methods in the Detection of Bone Metastases in Patients with Medullary Thyroid Cancer: a Report of a Series of 31 Cases.

Cristina Emiko Ueda1, Paulo Schiavom Duarte1, Luciana Audi de Castroneves2, George Barbério Coura-Filho1, Heitor Naoki Sado1,3, Marcelo Tatit Sapienza3, Ana Oliveira Hoff2, Carlos Alberto Buchpiguel1,3.   

Abstract

PURPOSE: To compare the 18F-NaF PET/CT studies (18F-NaF) with other imaging methods in the detection of skeletal metastases (SM) in patients with medullary thyroid cancer (MTC).
METHODS: We retrospectively analyzed 31 patients with MTC who performed 18F-NaF to assess SM. The results of the 18F-NaF were compared with other imaging methods performed for metastasis detection: 99Tc-MDP bone scan (BS), magnetic resonance imaging (MRI), contrast-enhanced CT (CT), and 68Ga-Dotatate and 18F-FDG PET/CT studies. A qualitative analysis comparing the 18F-NaF findings with the ones of the other methods was performed, and the results were classified as superior (>), equal (=), and inferior (<).
RESULTS: Eleven patients had no bone metastases detected on any of the imaging methods used. Twenty patients presented SM depicted on 18F-NaF. Of these 20 patients, 12 performed bone scan (in 9 18F-NaF > BS and in 3 18F-NaF = BS), 1 performed 18F-FDG (18F-NaF > 18F-FDG), 4 performed 68Ga-Dotatate (in 2 18F-NaF > 68Ga-Dotatate and in 2 18F-NaF = 68Ga-Dotatate), 20 performed CT of at least one body segment (in 15 18F-NaF = CT and in 5 18F-NaF > CT), and 16 performed MRI of at least one body segment, and in all of them, the 18F-NaF was equal to the MRI. Beside this, the 18F-NaF detected SM in body segments not routinely scanned in MRI and CT.
CONCLUSION: In patients with MTC, the 18F-NaF seems to be equal or superior to other imaging modalities in the detection of SM and allows the analysis of the whole skeletal in a single study. © Korean Society of Nuclear Medicine 2020.

Entities:  

Keywords:  18F; 18F-NaF; Bone metastases; Fluorine; Medullary thyroid carcinoma; PET/CT

Year:  2020        PMID: 33281999      PMCID: PMC7704988          DOI: 10.1007/s13139-020-00666-3

Source DB:  PubMed          Journal:  Nucl Med Mol Imaging        ISSN: 1869-3474


  32 in total

1.  [Nuclear Medicine in Germany. Updated key data and trends from official statistics].

Authors:  Dirk Hellwig; Jörg Marienhagen; Karin Menhart; Jirka Grosse
Journal:  Nuklearmedizin       Date:  2017-03-07       Impact factor: 1.379

2.  Radioisotopes: The medical testing crisis.

Authors:  Richard Van Noorden
Journal:  Nature       Date:  2013-12-12       Impact factor: 49.962

Review 3.  ACR appropriateness criteria on metastatic bone disease.

Authors:  Catherine C Roberts; Richard H Daffner; Barbara N Weissman; Laura Bancroft; D Lee Bennett; Judy S Blebea; Michael A Bruno; Ian Blair Fries; Isabelle M Germano; Langston Holly; Jon A Jacobson; Jonathan S Luchs; William B Morrison; Jeffrey J Olson; William K Payne; Charles S Resnik; Mark E Schweitzer; Leanne L Seeger; Mihra Taljanovic; James N Wise; Stephen T Lutz
Journal:  J Am Coll Radiol       Date:  2010-06       Impact factor: 5.532

Review 4.  Diagnostic value of MRI in comparison to scintigraphy, PET, MS-CT and PET/CT for the detection of metastases of bone.

Authors:  N Ghanem; M Uhl; I Brink; O Schäfer; T Kelly; E Moser; M Langer
Journal:  Eur J Radiol       Date:  2005-07       Impact factor: 3.528

5.  The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP Planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT.

Authors:  Einat Even-Sapir; Ur Metser; Eyal Mishani; Gennady Lievshitz; Hedva Lerman; Ilan Leibovitch
Journal:  J Nucl Med       Date:  2006-02       Impact factor: 10.057

6.  A Prospective Study Comparing 99mTc-Hydroxyethylene-Diphosphonate Planar Bone Scintigraphy and Whole-Body SPECT/CT with 18F-Fluoride PET/CT and 18F-Fluoride PET/MRI for Diagnosing Bone Metastases.

Authors:  Johan Löfgren; Jann Mortensen; Sine H Rasmussen; Claus Madsen; Annika Loft; Adam E Hansen; Peter Oturai; Karl Erik Jensen; Mette Louise Mørk; Michala Reichkendler; Liselotte Højgaard; Barbara M Fischer
Journal:  J Nucl Med       Date:  2017-08-10       Impact factor: 10.057

7.  Bone Metastases and Skeletal-Related Events in Medullary Thyroid Carcinoma.

Authors:  Jian Yu Xu; William A Murphy; Denái R Milton; Camilo Jimenez; Sarika N Rao; Mouhammed Amir Habra; Steven G Waguespack; Ramona Dadu; Robert F Gagel; Anita K Ying; Maria E Cabanillas; Steven P Weitzman; Naifa L Busaidy; Rena V Sellin; Elizabeth Grubbs; Steven I Sherman; Mimi I Hu
Journal:  J Clin Endocrinol Metab       Date:  2016-09-23       Impact factor: 5.958

8.  Current Status of Nuclear Medicine Practice in Latin America and the Caribbean.

Authors:  Diana Páez; Pilar Orellana; Claudia Gutiérrez; Raúl Ramirez; Fernando Mut; Leonel Torres
Journal:  J Nucl Med       Date:  2015-07-30       Impact factor: 10.057

9.  Imaging medullary thyroid carcinoma with persistent elevated calcitonin levels.

Authors:  Anne Laure Giraudet; Daniel Vanel; Sophie Leboulleux; Anne Aupérin; Clarisse Dromain; Linda Chami; Noël Ny Tovo; Jean Lumbroso; Nathalie Lassau; Guillaume Bonniaud; Dana Hartl; Jean-Paul Travagli; Eric Baudin; Martin Schlumberger
Journal:  J Clin Endocrinol Metab       Date:  2007-08-28       Impact factor: 5.958

10.  Bone and Calcified Soft Tissue Metastases of Medullary Thyroid Carcinoma Better Characterized on 18F-Fluoride PET/CT than on 68Ga-Dotatate PET/CT.

Authors:  Paulo Schiavom Duarte; Luciana Audi de Castroneves; Heitor Naoki Sado; Marcelo Tatit Sapienza; Ana Amélia Fialho de Oliveira Hoff; Carlos Alberto Buchpiguel
Journal:  Nucl Med Mol Imaging       Date:  2018-06-04
View more
  1 in total

Review 1.  Imaging medullary thyroid cancer patients with detectable serum markers: state of the art and future perspectives.

Authors:  Michele Klain; Julien Hadoux; Carmela Nappi; Monica Finessi; Raffaele Ambrosio; Martin Schlumberger; Alberto Cuocolo; Désirée Deandreis; Domenico Salvatore
Journal:  Endocrine       Date:  2021-11-08       Impact factor: 3.633

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.